Study findings showed 86% of patients had early and sustained neutrophil recovery at 100 days. The Food and Drug Administration (FDA) has approved Omisirge ® (omidubicel-onlv) for adults and pediatric ...

The U.S. Food and Drug Administration has approved Omisirge (omidubicel-onlv) as the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia (SAA). Omisirge is ...

Aplastic anaemia is a rare, life‐threatening disorder of the bone marrow characterised by pancytopenia and a hypocellular marrow. The primary pathophysiology involves immune-mediated destruction of ...

Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.

The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...